ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 79 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $421,762 | -43.7% | 79,430 | +1.1% | 0.00% | -100.0% |
| Q2 2023 | $748,600 | +125504.0% | 78,552 | +45.0% | 0.00% | 0.0% |
| Q1 2023 | $596 | -24.6% | 54,166 | +1.5% | 0.00% | 0.0% |
| Q4 2022 | $790 | -99.9% | 53,377 | +19.5% | 0.00% | 0.0% |
| Q3 2022 | $854,000 | -3.1% | 44,674 | +8.1% | 0.00% | 0.0% |
| Q2 2022 | $881,000 | +29.4% | 41,345 | +17.0% | 0.00% | 0.0% |
| Q1 2022 | $681,000 | -7.7% | 35,340 | -0.7% | 0.00% | 0.0% |
| Q4 2021 | $738,000 | -13.2% | 35,602 | +0.1% | 0.00% | 0.0% |
| Q3 2021 | $850,000 | -9.2% | 35,584 | +3.8% | 0.00% | 0.0% |
| Q2 2021 | $936,000 | +60.8% | 34,284 | +70.3% | 0.00% | 0.0% |
| Q1 2021 | $582,000 | +3.0% | 20,133 | +0.2% | 0.00% | 0.0% |
| Q4 2020 | $565,000 | +13.7% | 20,088 | +18.3% | 0.00% | 0.0% |
| Q3 2020 | $497,000 | +48.8% | 16,975 | +53.9% | 0.00% | 0.0% |
| Q2 2020 | $334,000 | +13.6% | 11,031 | +11.6% | 0.00% | 0.0% |
| Q1 2020 | $294,000 | – | 9,881 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |